FDA Grants BBT-877 For Orphan Drug For Iapathic Pulmonary Fibrosis
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, South Korea's Bridge Bios
company(http:// announcedthat the u.SFood andDrug(http://Administration (
FDA(http://) has granted BBT-877 treatment for iacotic pulmonary fibrosis (IPF) orphan drug eligibilityBBT-887
BBT-887 is a powerful, best-in-class self-secretion motor factor (Autotaxin, ATX) inhibitor, an enzyme that participates in inflammation and fibrosis by generating lipid signaling moleculesEarly compounds of BBT-887 were first discovered by LegoChem Biosciences, a Korean biotech company2017, Bridge Biotherapeutics was granted the exclusive global license to further develop the drugIn August 2018, Bridge Biotherapeutics presented the results of the preclinical study of BBT-877 at the IPF Summit, which raised interest and concern among respiratory experts about the effectiveness and safety of the drug candidateData show that BBT-877 may be the best-in-class compound compared to the compounds currently in the pipeline developed BBT-877 is bridge Biotherapeutics' second molecule to receive FDA approval for clinical studies, and another molecule, BBT-401, is currently in Phase II clinical, the first anti-ubiquinone-connected enzyme Pellino-1 compound to treat ulcerative colitis, and is expected to be the first drug in the selective patient group in February
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
